AHIP, PhRMA Try to Control Narrative as Heat on PBMs Intensifies
Executive Summary
As health insurance lobby launches advertising campaign to defend ‘evidence-based, market-driven tools,’ drug firms point out the connection between insurers and pharmacy benefit managers.
You may also be interested in...
Drug Pricing Reforms In US Congress: Legacy Systems vs. Cutting-Edge
A House hearing on bipartisan drug pricing reform bills continues the intense focus on the role of pharmacy benefit managers. But it also shows continued interest in finding ways to make payment systems work for cutting edge gene therapies.
Rx Oversight Issues at Federal Workers’ Comp Program Endangered Patients, Audit Says
OWCP says that hiring a PBM will address overprescribing and cost concerns, but a consultant who participated in the audit is skeptical.
Even As PBMs Face Reckoning, Formulary Exclusions Rise Again In 2023
Congressional scrutiny aside, ‘the rebate model remains alive and well’ as the big three pharmacy benefit managers exclude around 600 drugs each from their formularies.